Chemotherapy Response Score in Ovarian Cancer Patients: An Overview of Its Clinical Utility

被引:4
作者
Rodolakis, Ioannis [1 ]
Pergialiotis, Vasilios [1 ]
Liontos, Michalis [2 ]
Haidopoulos, Dimitrios [1 ]
Loutradis, Dimitrios [1 ]
Rodolakis, Alexandros [1 ]
Bamias, Aristotelis [2 ]
Thomakos, Nikolaos [1 ]
机构
[1] Natl & Kapodistrian Univ Athens, Alexandra Hosp, 1st Dept Obstet & Gynecol, Div Gynecol Oncol, Athens 10679, Greece
[2] Natl & Kapodistrian Univ Athens, Alexandra Hosp, Dept Clin Therapeut, Athens 11527, Greece
关键词
chemotherapy response; ovarian cancer; interval debulking surgery; progression-free survival; overall survival; INTERVAL DEBULKING SURGERY; NEOADJUVANT CHEMOTHERAPY; EPITHELIAL OVARIAN; SYSTEM;
D O I
10.3390/jcm12062155
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The chemotherapy response score has been developed over the last few years as a predictive index of survival outcomes for patients with advanced-stage epithelial ovarian cancer undergoing interval debulking surgery. While its importance in predicting patients at risk of developing recurrences earlier seems to be important, its accuracy in determining patients with a shorter overall survival remains arbitrary. Moreover, standardization of the actual scoring system that was initially developed as a 6-tiered score and adopted as a 3-tiered score is still needed, as several studies suggest that a 2-tiered system is preferable. Given its actual importance in detecting patients with shorter progression-free survival, research should also focus on the actual predictive value of determining patients with platinum resistance, as a suboptimal patient response to standard neoadjuvant chemotherapy might help determine patients at risk of an earlier recurrence. In the present review, we summarize current knowledge retrieved from studies addressing outcomes related to the chemotherapy response score in epithelial ovarian cancer patients undergoing neoadjuvant chemotherapy and discuss differences in outcome reporting to help provide directions for further research.
引用
收藏
页数:6
相关论文
共 25 条
  • [1] Chemotherapy Response Score: Development and Validation of a System to Quantify Histopathologic Response to Neoadjuvant Chemotherapy in Tubo-Ovarian High-Grade Serous Carcinoma
    Boehm, Steffen
    Faruqi, Asma
    Said, Ian
    Lockley, Michelle
    Brockbank, Elly
    Jeyarajah, Arjun
    Fitzpatrick, Amanda
    Ennis, Darren
    Dowe, Thomas
    Santos, Jennifer L.
    Cook, Linda S.
    Tinker, Anna V.
    Le, Nhu D.
    Gilks, C. Blake
    Singh, Naveena
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (22) : 2457 - U73
  • [2] Cancer Statistics in China, 2015
    Chen, Wanqing
    Zheng, Rongshou
    Baade, Peter D.
    Zhang, Siwei
    Zeng, Hongmei
    Bray, Freddie
    Jemal, Ahmedin
    Yu, Xue Qin
    He, Jie
    [J]. CA-A CANCER JOURNAL FOR CLINICIANS, 2016, 66 (02) : 115 - 132
  • [3] Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data
    Cohen, Paul A.
    Powell, Aime
    Bohm, Steffen
    Gilks, C. Blake
    Stewart, Colin J. R.
    Meniawy, Tarek M.
    Bulsara, Max
    Avril, Stefanie
    Brockbank, Eleanor C.
    Bosse, Tjalling
    de Azevedo Focchi, Gustavo Rubino
    Ganesan, Raji
    Glasspool, Rosalind M.
    Howitt, Brooke E.
    Kim, Hyun-Soo
    Lee, Jung-Yun
    Le, Nhu D.
    Lockley, Michelle
    Manchanda, Ranjit
    Mandalia, Trupti
    McCluggage, W. Glenn
    McNeish, Iain
    Midha, Divya
    Srinivasan, Radhika
    Tan, Yun Yi
    van der Griend, Rachael
    Yunokawa, Mayu
    Zannoni, Gian F.
    Singh, Naveena
    [J]. GYNECOLOGIC ONCOLOGY, 2019, 154 (02) : 441 - 448
  • [4] ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease
    Colombo, N.
    Sessa, C.
    du Bois, A.
    Ledermann, J.
    McCluggage, W. G.
    McNeish, I.
    Morice, P.
    Pignata, S.
    Ray-Coquard, I.
    Vergote, I.
    Baert, T.
    Belaroussi, I.
    Dashora, A.
    Olbrecht, S.
    Planchamp, F.
    Querleu, D.
    Baert, T.
    Banerjee, S.
    Belaroussi, I.
    Blecharz, P.
    Bruchim, I.
    Cibula, D.
    Colombo, N.
    Concin, N.
    Davidson, B.
    Dashora, A.
    Devouassoux-Shisheboran, M.
    du Bois, A.
    Ferrero, A.
    Glasspool, R.
    Gonzalez-Martin, A.
    Heinzelmann-Schwarz, V.
    Joly, F.
    Kim, J. W.
    Kridelka, F.
    Ledermann, J.
    Lorusso, D.
    Mahner, S.
    McCluggage, W. G.
    McNeish, I.
    Mikami, M.
    Mirza, M. R.
    Morice, P.
    Nicum, S.
    Olbrecht, S.
    O'Donnell, D. M.
    Pautier, P.
    Planchamp, F.
    Pignata, S.
    Querleu, D.
    [J]. ANNALS OF ONCOLOGY, 2019, 30 (05) : 672 - 705
  • [5] Investigating the Impact of Ultra-Radical Surgery on Survival in Advanced Ovarian Cancer Using Population-Based Data in a Multicentre UK Study
    Cummins, Carole
    Kumar, Satyam
    Long, Joanna
    Balega, Janos
    Broadhead, Tim
    Duncan, Timothy
    Edmondson, Richard J.
    Fotopoulou, Christina
    Glasspool, Rosalind M.
    Kolomainen, Desiree
    Leeson, Simon
    Manchanda, Ranjit
    Morrison, Jo
    Naik, Raj
    Tidy, John A.
    Wood, Nick
    Sundar, Sudha
    [J]. CANCERS, 2022, 14 (18)
  • [6] Assessment of a Chemotherapy Response Score (CRS) System for Tubo-Ovarian High-Grade Serous Carcinoma (HGSC)
    Ditzel, Helena M.
    Strickland, Kyle C.
    Meserve, Emily E.
    Stover, Elizabeth
    Konstantinopoulos, Panagiotis A.
    Matulonis, Ursula A.
    Muto, Michael G.
    Liu, Joyce F.
    Feltmate, Colleen
    Horowitz, Neil
    Berkowitz, Ross S.
    Gupta, Mamta
    Hecht, Jonathan L.
    Lin, Douglas I.
    Jochumsen, Kirsten M.
    Welch, William R.
    Hirsch, Michelle S.
    Quade, Bradley J.
    Lee, Kenneth R.
    Crum, Christopher P.
    Mutter, George L.
    Nucci, Marisa R.
    Howitt, Brooke E.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 2019, 38 (03) : 230 - 240
  • [7] Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850)
    Fagotti, Anna
    Ferrandina, Maria Gabriella
    Vizzielli, Giuseppe
    Pasciuto, Tina
    Fanfani, Francesco
    Gallotta, Valerio
    Margariti, Pasquale Alessandro
    Chiantera, Vito
    Costantini, Barbara
    Gueli Alletti, Salvatore
    Cosentino, Francesco
    Scambia, Giovanni
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2020, 30 (11) : 1657 - 1664
  • [8] Ferlay J., 2012, GLOBOCAN 2012 v1.0. Cancer Incidence Mortality Worldwide
  • [9] Maximal Effort Cytoreduction in Epithelial Ovarian Cancer: Perioperative Complications and Survival Outcomes from a Retrospective Cohort
    Haidopoulos, Dimitrios
    Pergialiotis, Vasilios
    Zachariou, Eleftherios
    Sapantzoglou, Ioakim
    Thomakos, Nikolaos
    Stamatakis, Emmanouil
    Alexakis, Nikolaos
    [J]. JOURNAL OF CLINICAL MEDICINE, 2023, 12 (02)
  • [10] Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial
    Katsumata, Noriyuki
    Yasuda, Makoto
    Isonishi, Seiji
    Takahashi, Fumiaki
    Michimae, Hirofumi
    Kimura, Eizo
    Aoki, Daisuke
    Jobo, Toshiko
    Kodama, Shoji
    Terauchi, Fumitoshi
    Sugiyama, Toru
    Ochiai, Kazunori
    [J]. LANCET ONCOLOGY, 2013, 14 (10) : 1020 - 1026